Безопасность и эффективность применения паливизумаба у детей с высоким риском тяжелой респираторно-синцитиальной вирусной инфекции в Российской Федерации
- Авторы: Намазова-Баранова Л.В1, Турти Т.В1, Кешишян Е.С2, Давыдова И.В1, Галустян А.В3, Harris B.4, Демская Е.Э5, Notario G.6, Schulz G.6, Kan-Dobrosky N.7
-
Учреждения:
- ФГБУ «Научный центр здоровья детей» МЗ РФ
- Московский научно-исследовательский институт педиатрии и детской хирургии Росмедтехнологий РФ, ГУ
- Санкт-Петербургский государственный педиатрический медицинский университет
- MedImmune
- ООО «ЭббВи»
- AbbVie Inc
- AbbVie GmbH & Co. KG
- Выпуск: № 1 (2016)
- Страницы: 43-50
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2073-4034/article/view/288566
- ID: 288566
Цитировать
Полный текст
Доступ предоставлен
Доступ платный или только для подписчиков
Аннотация
Полный текст
Об авторах
Л. В Намазова-Баранова
ФГБУ «Научный центр здоровья детей» МЗ РФ
Т. В Турти
ФГБУ «Научный центр здоровья детей» МЗ РФ
Е. С Кешишян
Московский научно-исследовательский институт педиатрии и детской хирургии Росмедтехнологий РФ, ГУ
И. В Давыдова
ФГБУ «Научный центр здоровья детей» МЗ РФ
А. В Галустян
Санкт-Петербургский государственный педиатрический медицинский университет
Brian Harris
MedImmuneGaithersburg, MD; USA
Е. Э Демская
ООО «ЭббВи»
Email: elena.demskaya@abbvie.com
д.м.н.
Gerard Notario
AbbVie IncNorth Chicago, IL; USA
Greg Schulz
AbbVie IncNorth Chicago, IL; USA
N. Kan-Dobrosky
AbbVie GmbH & Co. KG
Список литературы
- Nair H., Nokes D.J., Gessner B.D., Dherani M., Madhi S.A., Singleton R.J., O'Brien K.L., Roca A., Wright P.F., Bruce N., Chandran A., Theodoratou E., Sutanto A., Sedyaningsih E.R., Ngama M., Munywoki P.K., Kartasasmita C., Simoes E.A., Rudan I., Weber M.W., Campbell H. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010; 375(9725): 1545-55.
- Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003; 289(2): 179-86.
- Glezen W.P., Taber L.H., Frank A.L., Kasel J.A. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 1986; 140(6): 543-46.
- Aujard Y., Fauroux B. Risk factors for severe respiratory syncytial virus infection in infants. Respir. Med. 2002; 96(Suppl. B): 9-14.
- Mullins J.A., Lamonte A.C., Bresee J.S., Anderson L.J. Substantial variability in community respiratory syncytial virus season timing. Pediatr. Infect. Dis. J. 2003; 22(10): 857-62.
- Stensballe L.G., Devasundaram J.K., Simoes E.A. Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus. Pediatr. Infect. Dis. J. 2003; 22(Suppl. 2): 21-32.
- Dawson-Caswell M., Muncie H.L., Jr. Respiratory syncytial virus infection in children. Am. Fam. Physician. 2011; 83(2): 141-46.
- Ohuma E.O., Okiro E.A., Ochola R., Sande C.J., Cane P.A., Medley G.F., Bottomley C., Nokes D.J. The natural history of respiratory syncytial virus in a birth cohort: the influence of age and previous infection on reinfection and disease. Am. J. Epidemiol. 2012; 176(9): 794-802.
- Graham B.S. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol. Rev. 2011; 239(1): 149-66.
- Johnson S., Oliver C., Prince G.A., Hemming V.G., Pfarr D.S., Wang S.C., Dormitzer M., O'Grady J., Koenig S., Tamura J.K., Woods R., Bansal G., Couchenour D., Tsao E., Hall W.C., Young J.F. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 1997; 176(5): 1215-24.
- Feltes T.F., Cabalka A.K., Meissner H.C., Piazza F.M., Carlin D.A., Top F.H. Jr, Connor E.M., Sondheimer H.M. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J. Pediatr. 2003; 143(4): 532-40.
- The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998; 102(3): 531-37.
- Palivizumab. Full Prescribing Information, MedImmune, Gaithersburg, M.D., 2014.
- European Medicines Agency. Synagis European Authorisation. Available at: http://www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000257/human_med_001070.jsp&mid=WC0b01ac058001d124. Accessed December 9, 2014.
- Tatochenko V., Uchaikin V., Gorelov A., et al. Epidemiology of respiratory syncytial virus in children =2 years of age hospitalized with lower respiratory tract infections in the Russian Federation: a prospective, multicenter study. Clin Epidemiol. 2010; 2: 221-27.
- Gooch K.L., Notario G.F., Schulz G., et al. Comparison of risk factors between preterm and term infants hospitalized for severe respiratory syncytial virus in the Russian Federation. Int. J. Womens Health. 2011; 3: 133-38.
- Carbonell-Estrany X., Simoes E.A., Dagan R., et al., Motavizumab Study Group. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics. 2010; 125(1): e35-51.
- Feltes T.F., Sondheimer H.M., Tulloh R.M., et al., Motavizumab Cardiac Study Group. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr. Res. 2011; 70(2): 186-91.
- Turti T.V., Baibarina E.N., Degtiareva E.A., et al. A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation. BMC Res. Notes. 2012; 5: 484.
- Muntanola A. The importance of geographical differences in pediatric clinical trials. In: Mulberg A., Silber S., van den Anker J., eds. Pediatric Drug Development: Concepts and Applications. New York: John Wiley & Sons; 2009: 437-49.
- Mentz R.J., Kaski J.C., Dan G.A., et al. Implications of geographical variation on clinical outcomes of cardiovascular trials. Am. Heart J. 2012; 164(3): 303-12.
- European Medicines Agency. Note for guidance on ethnic factors in the acceptability of foreign clinical data (CPMP/ICH/189/95). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002842.pdf. Accessed April 16, 2015.
- Pedraz C., Carbonell-Estrany X., Figueras-Aloy J., Quero J. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr. Infect. Dis. J. 2003; 22(9): 823-27.